While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Medically reviewed by Shadi Hamdeh, MDMedically reviewed by Shadi Hamdeh, MD Humira (adalimumab) side effects may include ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Investing some of your tax refund in stocks can help build your portfolio. The three stocks below trade at forward earnings ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, was among a trio who received this year’s Nobel Prize in Chemistry.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

AbbVie's positioning in this niche is intact thanks to its superstar products like Rinvoq, Skyrizi, and Humira. Humira has been dominating the space for almost two decades until its patent expired ...

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...

Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...